Key Drivers
- Exceptional gross margin
- Deep negative cashflow
- High financial leverage
AIAI Summary
Syndax's transformation into a commercial-revenue company means the investment thesis now hinges on sustaining Rx starts/persistence and converting growing Revuforj/Niktimvo sales (and partner revenues) into positive cash flow rather than binary trial outcomes. The critical risk/opportunity is gross‑to‑net and payer mix—if gross‑to‑net tightens below management guidance and cash burn falls, upside is viable; if it worsens (>25% or persistent transplant-driven lumpy demand) the company likely needs dilutive financing.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Exceptional gross margin
- •Deep negative cashflow
- •High financial leverage
SNDX pairs exceptional gross margins and healthy near-term liquidity with heavy R&D-driven cash burn, large operating losses and very high leverage, making the current valuation appear rich versus fundamentals.
Price Behavior
Key Price Behavior Insights:
- •Above last month SMA
- •Reclaimed resistance
- •RSI near 25
Price is trading above its last month SMA and has reclaimed the ~$24.40 March resistance after clearing the Mar 3–6 consolidation—momentum is positive but a ~25 RSI signals possible weakness, so watch for a convincing close above $24.40 or a break below early-March support to confirm direction.
Cleared
Sentiment & News
Key News Insights:
- •Rapid launches
- •Strong stock surge
- •Continued losses
Syndax delivered a commercial inflection with $172.4M FY2025 revenue driven by fast Revuforj and Niktimvo launches, strong stock reaction and mixed institutional trading despite ongoing GAAP losses and upcoming clinical catalysts.
The revenue ramp and market enthusiasm position Syndax for accelerated commercial growth, but execution on clinical readouts and sustained margin improvement will determine long-term valuation
Similar Companies in Healthcare
Other companies in the same sector with AI ratings